BACKGROUND: Advanced squamous cell carcinomas of the head and neck region were often treated with combined radio-chemotherapy. Radiotherapy allows a focused treatment of the tumor, and healthy tissue can be protected from radiation. Chemotherapy, however, is mostly given systemically and the unwanted negative side effects also develop in many other organs. AIM OF THE STUDY: Locoregional application of chemotherapeutic agents with Magnetic Drug Targeting on an animal experimental study. METHODS AND RESULTS: Magnetic Drug Targeting is a new approach to the locoregional treatment of tumors. Ferrofluids (colloidal dispersion of magnetic nanoparticles) were reversibly bound to chemotherapeutic agents and injected intra-arterially, while focused with an external magnetic field to a certain body compartment (i.e. the tumor). With only 20% or 50% percent of the regular systemic chemotherapeutic dose, we achieved an up to 26 times higher concentration in the tumor region with this application compared to the usual systemic administration. CONCLUSION: Magnetic Drug Targeting offers an unique opportunity to treat tumors locoregionally with chemotherapeutic agents.
BACKGROUND: Advanced squamous cell carcinomas of the head and neck region were often treated with combined radio-chemotherapy. Radiotherapy allows a focused treatment of the tumor, and healthy tissue can be protected from radiation. Chemotherapy, however, is mostly given systemically and the unwanted negative side effects also develop in many other organs. AIM OF THE STUDY: Locoregional application of chemotherapeutic agents with Magnetic Drug Targeting on an animal experimental study. METHODS AND RESULTS: Magnetic Drug Targeting is a new approach to the locoregional treatment of tumors. Ferrofluids (colloidal dispersion of magnetic nanoparticles) were reversibly bound to chemotherapeutic agents and injected intra-arterially, while focused with an external magnetic field to a certain body compartment (i.e. the tumor). With only 20% or 50% percent of the regular systemic chemotherapeutic dose, we achieved an up to 26 times higher concentration in the tumor region with this application compared to the usual systemic administration. CONCLUSION: Magnetic Drug Targeting offers an unique opportunity to treat tumors locoregionally with chemotherapeutic agents.
Authors: C Alexiou; W Arnold; R J Klein; F G Parak; P Hulin; C Bergemann; W Erhardt; S Wagenpfeil; A S Lübbe Journal: Cancer Res Date: 2000-12-01 Impact factor: 12.701
Authors: A S Lübbe; C Bergemann; H Riess; F Schriever; P Reichardt; K Possinger; M Matthias; B Dörken; F Herrmann; R Gürtler; P Hohenberger; N Haas; R Sohr; B Sander; A J Lemke; D Ohlendorf; W Huhnt; D Huhn Journal: Cancer Res Date: 1996-10-15 Impact factor: 12.701
Authors: K T Robbins; D Vicario; S Seagren; R Weisman; P Pellitteri; C Kerber; L Orloff; G Los; S B Howell Journal: Am J Surg Date: 1994-11 Impact factor: 2.565
Authors: J A Werner; W Kehrl; A Pluzanska; O Arndt; K M Lavery; J Glaholm; A Dietz; G Dyckhoff; S Maune; M E Stewart; E K Orenberg; R D Leavitt Journal: Br J Cancer Date: 2002-10-21 Impact factor: 7.640
Authors: Guenther Hasenpusch; Johannes Geiger; Kai Wagner; Olga Mykhaylyk; Frank Wiekhorst; Lutz Trahms; Alexandra Heidsieck; Bernhard Gleich; Christian Bergemann; Manish K Aneja; Carsten Rudolph Journal: Pharm Res Date: 2012-01-21 Impact factor: 4.200
Authors: Boris Polyak; Ilia Fishbein; Michael Chorny; Ivan Alferiev; Darryl Williams; Ben Yellen; Gary Friedman; Robert J Levy Journal: Proc Natl Acad Sci U S A Date: 2008-01-08 Impact factor: 11.205
Authors: Christina Janko; Stephan Dürr; Luis E Munoz; Stefan Lyer; Ricardo Chaurio; Rainer Tietze; Sarah von Löhneysen; Christine Schorn; Martin Herrmann; Christoph Alexiou Journal: Int J Mol Sci Date: 2013-04-02 Impact factor: 5.923